Patents Examined by Vankataraman Balasubramanian
  • 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof
    Patent number: 9951040
    Abstract: The present invention describes heterocyclic compounds of general Formula 1 and their method of preparation thereof. The present invention describes general Formula 1 which inhibits phosphoinositide 3-kinase (PI3K) and can be used as the anticancer agents.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 24, 2018
    Assignee: Council of Scientific and Industrial Research
    Inventors: Thanusha Thatikonda, Suresh Kumar, Umed Singh, Priya Mahajan, Girish Mahajan, Amit Nargotra, Fayaz Malik, Dilip Manikrao Mondhe, Ram Asrey Vishwakarma, Parvinder Pal Singh
  • Biaryl kinase inhibitors
    Patent number: 9902722
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • Solid forms of Ivacaftor and processes for the preparation thereof
    Patent number: 9809551
    Abstract: Provided herein is a polymorphic form of Ivacaftor, namely APO-I, as well as processes for the preparation and pharmaceutical compositions of the same. Also, provided is a new solvate of Ivacaftor, processes for its preparation and use in the preparation of pure Ivacaftor.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 7, 2017
    Assignee: Apotex Inc.
    Inventors: Padiyath Mohammed Akbarali, Kintali Venkata Ramana, Heggadde Nanjunda Bhatta Shreenivasa Murthy, Sankaran Suresh Kumar, Ekkaluru Vijaya Bhaskar, Nechipadappu Sunil Kumar, Karad Manjunath
  • Process for the preparation of toltrazuril and an intermediate useful for its preparation
    Patent number: 9802906
    Abstract: Disclosed is a process for the preparation of toltrazuril of formula (I) via the intermediate N-methyl-N?-[3-methyl-4-[4-[(trifluoromethyl)thio]phenoxy]phenyl] imidodicarbonic diamide of formula (III) wherein intermediate (III) is obtained via a novel intermediate without the use of potentially hazardous reagents or potentially unstable intermediates.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: October 31, 2017
    Assignee: ERREGIERRE S.P.A.
    Inventors: Massimo Ferrari, Daniele De Zani, Matteo Bonaldi
  • N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
    Patent number: 9724350
    Abstract: Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 8, 2017
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jeremy Travins, Luke Utley
  • Pyrazole compounds useful as protein kinase inhibitors
    Patent number: 6656939
    Abstract: This invention describes novel pyrazole compounds of formula III: wherein Z1, Z2, and Z3 are as described in the specification; Q is —S—, —O—, —N(R4)—, or —CH(R6)—; R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: December 2, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David Bebbington, Jean-Damien Charrier